Literature DB >> 29121202

Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.

W Charles Huskins1, Vance G Fowler2, Scott Evans3.   

Abstract

Clinical trials with adaptive designs use data that accumulate during the course of the study to modify study elements in a prespecified manner. The goal is to provide flexibility such that a trial can serve as a definitive test of its primary hypothesis, preferably in a shorter time period, involving fewer human subjects, and at lower cost. Elements that may be modified include the sample size, end points, eligible population, randomization ratio, and interventions. Accumulating data used to drive these modifications include the outcomes, subject enrollment (including factors associated with the outcomes), and information about the application of the interventions. This review discusses the types of adaptive designs for clinical trials, emphasizing their advantages and limitations in comparison with conventional designs, and opportunities for applying these designs to healthcare epidemiology research, including studies of interventions to prevent healthcare-associated infections, combat antimicrobial resistance, and improve antimicrobial stewardship.

Entities:  

Mesh:

Year:  2018        PMID: 29121202      PMCID: PMC6018921          DOI: 10.1093/cid/cix907

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  Modification of sample size in group sequential clinical trials.

Authors:  L Cui; H M Hung; S J Wang
Journal:  Biometrics       Date:  1999-09       Impact factor: 2.571

2.  Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.

Authors:  Qing Liu; George Y H Chi
Journal:  J Biopharm Stat       Date:  2010-11       Impact factor: 1.051

3.  Adaptive Randomization of Neratinib in Early Breast Cancer.

Authors:  Heikki Joensuu
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

4.  MASTERMIND: Bringing Microbial Diagnostics to the Clinic.

Authors:  Robin Patel; Ephraim L Tsalik; Elizabeth Petzold; Vance G Fowler; Jeffrey D Klausner; Scott Evans
Journal:  Clin Infect Dis       Date:  2016-12-07       Impact factor: 9.079

5.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

6.  Vital Directions for Health and Health Care: Priorities From a National Academy of Medicine Initiative.

Authors:  Victor J Dzau; Mark B McClellan; J Michael McGinnis; Sheila P Burke; Molly J Coye; Angela Diaz; Thomas A Daschle; William H Frist; Martha Gaines; Margaret A Hamburg; Jane E Henney; Shiriki Kumanyika; Michael O Leavitt; Ruth M Parker; Lewis G Sandy; Leonard D Schaeffer; Glenn D Steele; Pamela Thompson; Elias Zerhouni
Journal:  JAMA       Date:  2017-04-11       Impact factor: 56.272

Review 7.  Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Yohei Doi; Robert A Bonomo; David C Hooper; Keith S Kaye; James R Johnson; Cornelius J Clancy; Joshua T Thaden; Martin E Stryjewski; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

8.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

9.  Some recommendations for multi-arm multi-stage trials.

Authors:  James Wason; Dominic Magirr; Martin Law; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2012-12-12       Impact factor: 3.021

10.  A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.

Authors:  Daniel J Bratton; Patrick P J Phillips; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-11-14       Impact factor: 4.615

View more
  6 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Resist the Temptation of Response-Adaptive Randomization.

Authors:  Michael Proschan; Scott Evans
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

Review 3.  The Bayesian Design of Adaptive Clinical Trials.

Authors:  Alessandra Giovagnoli
Journal:  Int J Environ Res Public Health       Date:  2021-01-10       Impact factor: 3.390

4.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

5.  Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial.

Authors:  Guofa Zhou; Ming-Chieh Lee; Harrysone E Atieli; John I Githure; Andrew K Githeko; James W Kazura; Guiyun Yan
Journal:  Trials       Date:  2020-07-20       Impact factor: 2.279

Review 6.  Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations.

Authors:  Paula Rojas-Garcia; Simon van der Pol; Antoinette D I van Asselt; Maarten J Postma; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló; Marino González; Fernando Antoñanzas
Journal:  Antibiotics (Basel)       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.